Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...

AETERNA ZENTARIS ANNOUNCES ABSTRACT OF RESULTS FROM FIRST PEDIATRIC STUDY OF MACIMORELIN ACCEPTED FOR PRESENTATION AT THE 22ND EUROPEAN CONGRESS OF ENDOCRINOLOGY CHARLESTON, S.C., July 30, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...

AETERNA ZENTARIS ANNOUNCES CLOSING OF $12 MILLION PUBLIC OFFERING CHARLESTON, S.C., July 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...